Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Glen J. Weiss, M.D.

Profile Picture

Sackler School of Medicine, Tel AvivMD05/2001Medicine
W.P. Carey School of Business, Tempe, AZMBA12/2013Business
Phoenix Business Journal 40 under 40
AZ Business Magazine Healthcare Leadership Award: Researcher


Available: 10/10/18, Expires: 10/09/19

Interested students would work with Dr. Glen Weiss to evaluate financial conflicts of academic non-U.S. practicing oncologists. While CMS Open Payments provides a public searchable database to evaluate FCOI amongst U.S. practicing physicians, there is no searchable tool for monetary FCOI for non-U.S. based practitioners. Students will learn to design a survey, how to seek the appropriate Institutional Review Board approval, compile survey results, analyze, and develop a written product for presentation and/or peer-reviewed publication. Most of this work will be computer-based and virtual.

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Lin CC, Arkenau HT, Lu S, Sachdev J, de Castro Carpeño J, Mita M, Dziadziuszko R, Su WC, Bobilev D, Hughes L, Chan J, Zhang ZY, Weiss GJ. A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas. Br J Cancer. 2019 Jun 20. PMID: 31217479.
  2. Addeo A, Banna GL, Weiss GJ. Tumor Mutation Burden-From Hopes to Doubts. JAMA Oncol. 2019 May 30. PMID: 31145420.
  3. Addeo A, Weiss GJ, Gyawali B. Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis. JAMA Netw Open. 2019 May 03; 2(5):e193684. PMID: 31074821.
  4. Weiss GJ, Blaydorn L, Beck J, Bornemann-Kolatzki K, Urnovitz H, Schütz E, Khemka V. Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Invest New Drugs. 2019 Apr 24. PMID: 31020607.
  5. Weiss GJ, Addeo A. Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer. N Engl J Med. 2019 02 28; 380(9):888-889. PMID: 30811920.
  6. Weiss GJ, Davis RB. Discordant financial conflicts of interest disclosures between clinical trial conference abstract and subsequent publication. PeerJ. 2019; 7:e6423. PMID: 30775185.
  7. Weiss GJ. A new era of treating advanced lung cancer is upon us. Transl Lung Cancer Res. 2018 Sep; 7(Suppl 3):S202-S205. PMID: 30393601.
  8. Morris SM, Subramanian J, Gel ES, Runger GC, Thompson EJ, Mallery DW, Weiss GJ. Correction: Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform. PLoS One. 2018; 13(6):e0200224. PMID: 29953541.
  9. Morris SM, Subramanian J, Gel ES, Runger GC, Thompson EJ, Mallery DW, Weiss GJ. Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform. PLoS One. 2018; 13(4):e0196556. PMID: 29702695.
  10. Morris S, Vachani A, Pass HI, Rom WN, Ryden K, Weiss GJ, Hogarth DK, Runger G, Richards D, Shelton T, Mallery DW. Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer. Int J Cancer. 2018 06 01; 142(11):2355-2362. PMID: 29313979.
    Citations:    Fields:    Translation:Humans
  11. Ramanathan RK, Weiss GJ, Posner RG, Rajeshkumar NV, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites EC, Hlavacek WS, Gatalica Z, Xiu J, Hidalgo M, Von Hoff DD, Barrett MT. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. J Gastrointest Oncol. 2017 Dec; 8(6):925-935. PMID: 29299351.
  12. Mitchell S, Williams JP, Bhatti H, Kachaamy T, Weber J, Weiss GJ. A retrospective matched cohort study evaluating the effects of percutaneous endoscopic gastrostomy feeding tubes on nutritional status and survival in patients with advanced gastroesophageal malignancies undergoing systemic anti-cancer therapy. PLoS One. 2017; 12(11):e0188628. PMID: 29186164.
    Citations:    Fields:    Translation:Humans
  13. Weiss GJ, Blaydorn L, Beck J, Bornemann-Kolatzki K, Urnovitz H, Schütz E, Khemka V. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Invest New Drugs. 2018 02; 36(1):96-102. PMID: 29119276.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  14. Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D. Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2018 01; 17(1):215-221. PMID: 29054986.
    Citations: 1     Fields:    
  15. Weiss GJ, Jameson G, Von Hoff DD, Valsasina B, Davite C, Di Giulio C, Fiorentini F, Alzani R, Carpinelli P, Di Sanzo A, Galvani A, Isacchi A, Ramanathan RK. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors. Invest New Drugs. 2018 02; 36(1):85-95. PMID: 28726132.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  16. Weiss GJ, Lohinai Z. Prophylactic cranial irradiation in small-cell lung cancer. Lancet Oncol. 2017 07; 18(7):e367. PMID: 28677570.
    Citations:    Fields:    Translation:Humans
  17. Weiss GJ, Waypa J, Blaydorn L, Coats J, McGahey K, Sangal A, Niu J, Lynch CA, Farley JH, Khemka V. A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). Br J Cancer. 2017 Jun 27; 117(1):33-40. PMID: 28588322.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  18. Weiss GJ, Byron SA, Aldrich J, Sangal A, Barilla H, Kiefer JA, Carpten JD, Craig DW, Whitsett TG. A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy. PLoS One. 2017; 12(6):e0179170. PMID: 28586388.
    Citations:    Fields:    Translation:HumansCellsCTClinical Trials
  19. Bahleda R, Grilley-Olson JE, Govindan R, Barlesi F, Greillier L, Perol M, Ray-Coquard I, Strumberg D, Schultheis B, Dy GK, Zalcman G, Weiss GJ, Walter AO, Kornacker M, Rajagopalan P, Henderson D, Nogai H, Ocker M, Soria JC. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. Br J Cancer. 2017 Jun 06; 116(12):1505-1512. PMID: 28463960.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  20. McGahey KE, Weiss GJ. Reviewing concomitant medications for participants in oncology clinical trials. Am J Health Syst Pharm. 2017 Apr 15; 74(8):580-586. PMID: 28389457.
    Citations: 1     Fields:    
  21. Oellerich M, Schütz E, Beck J, Kanzow P, Plowman PN, Weiss GJ, Walson PD. Using circulating cell-free DNA to monitor personalized cancer therapy. Crit Rev Clin Lab Sci. 2017 05; 54(3):205-218. PMID: 28393575.
    Citations: 10     Fields:    Translation:Humans
  22. Weiss GJ, Beck J, Braun DP, Bornemann-Kolatzki K, Barilla H, Cubello R, Quan W, Sangal A, Khemka V, Waypa J, Mitchell WM, Urnovitz H, Schütz E. Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy. Clin Cancer Res. 2017 Sep 01; 23(17):5074-5081. PMID: 28320758.
    Citations: 6     Fields:    Translation:HumansCells
  23. Burris HA, Bakewell S, Bendell JC, Infante J, Jones SF, Spigel DR, Weiss GJ, Ramanathan RK, Ogden A, Von Hoff D. Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort. ESMO Open. 2016; 1(6):e000154. PMID: 28848672.
    Citations: 2     
  24. Arnold SM, Chansky K, Leggas M, Thompson MA, Villano JL, Hamm J, Sanborn RE, Weiss GJ, Chatta G, Baggstrom MQ. Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553). Invest New Drugs. 2017 10; 35(5):608-615. PMID: 28204981.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  25. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696. PMID: 27836716.
    Citations: 39     Fields:    Translation:HumansCTClinical Trials
  26. Markman M, Kramer K, Alvarez RH, Weiss GJ, Ahn E, Daneker GW. Evaluating the Utility of a 'N-of-1' Precision Cancer Medicine Strategy: The Case for 'Time-to-Subsequent-Disease Progression'. Oncology. 2016; 91(6):299-301. PMID: 27705967.
    Citations: 2     Fields:    Translation:Humans
  27. Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Weiss GJ, Sachdev JC, Chadha M, Fulk M, Ejadi S, Mountz JM, Lotze MT, Toledo FG, Chu E, Jeffers M, Peña C, Xia C, Reif S, Genvresse I, Ramanathan RK. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas. Ann Oncol. 2016 10; 27(10):1928-40. PMID: 27672108.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  28. Von Hoff DD, Mita MM, Ramanathan RK, Weiss GJ, Mita AC, LoRusso PM, Burris HA, Hart LL, Low SC, Parsons DM, Zale SE, Summa JM, Youssoufian H, Sachdev JC. Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 07 01; 22(13):3157-63. PMID: 26847057.
    Citations: 24     Fields:    Translation:HumansCTClinical Trials
  29. Lohinai Z, Dome P, Szilagyi Z, Ostoros G, Moldvay J, Hegedus B, Dome B, Weiss GJ. From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC). PLoS One. 2016; 11(1):e0144797. PMID: 26735301.
    Citations: 3     Fields:    Translation:Humans
  30. Weiss GJ. Precision medicine: lessons learned from the SHIVA trial. Lancet Oncol. 2015 Dec; 16(16):e580. PMID: 26678199.
    Citations:    Fields:    Translation:Humans
  31. Salanti A, Clausen TM, Agerbæk MØ, Al Nakouzi N, Dahlbäck M, Oo HZ, Lee S, Gustavsson T, Rich JR, Hedberg BJ, Mao Y, Barington L, Pereira MA, LoBello J, Endo M, Fazli L, Soden J, Wang CK, Sander AF, Dagil R, Thrane S, Holst PJ, Meng L, Favero F, Weiss GJ, Nielsen MA, Freeth J, Nielsen TO, Zaia J, Tran NL, Trent J, Babcook JS, Theander TG, Sorensen PH, Daugaard M. Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. Cancer Cell. 2015 10 12; 28(4):500-514. PMID: 26461094.
    Citations: 22     Fields:    Translation:HumansAnimalsCells
  32. Patnaik A, Weiss GJ, Leonard JE, Rasco DW, Sachdev JC, Fisher TL, Winter LA, Reilly C, Parker RB, Mutz D, Blaydorn L, Tolcher AW, Zauderer M, Ramanathan RK. Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Feb 15; 22(4):827-36. PMID: 26446947.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  33. Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD, Faessel HM, Berger AJ, Burke K, Mulligan G, Dezube BJ, Harvey RD. Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Feb 15; 22(4):847-57. PMID: 26423795.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  34. Weiss GJ, Khemka V. Comparing two assays for clinical genomic profiling: the devil is in the data [Letter of clarification]. Onco Targets Ther. 2015; 8:2643. PMID: 26425099.
  35. Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von Hoff DD, Weiss GJ, Ramanathan RK, Zhang J, Habets G, Zhang Y, Burton EA, Visor G, Sanftner L, Severson P, Nguyen H, Kim MJ, Marimuthu A, Tsang G, Shellooe R, Gee C, West BL, Hirth P, Nolop K, van de Rijn M, Hsu HH, Peterfy C, Lin PS, Tong-Starksen S, Bollag G. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med. 2015 Jul 30; 373(5):428-37. PMID: 26222558.
  36. Patnaik A, Tolcher A, Beeram M, Nemunaitis J, Weiss GJ, Bhalla K, Agrawal M, Nichols G, Middleton S, Beryozkina A, Sarapa N, Peck R, Zhi J. Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2015 Sep; 76(3):587-95. PMID: 26210682.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  37. Weiss GJ. Influence of Robotic-Assisted Surgery on Readmission Burden. J Clin Oncol. 2015 Jul 01; 33(19):2229. PMID: 26014299.
  38. Weiss GJ, Hoff BR, Whitehead RP, Sangal A, Gingrich SA, Penny RJ, Mallery DW, Morris SM, Thompson EJ, Loesch DM, Khemka V. Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making. Onco Targets Ther. 2015; 8:959-67. PMID: 25960669.
    Citations: 4     
  39. Dearing KR, Weiss GJ. Translating next-generation sequencing from clinical trials to clinical practice for the treatment of advanced cancers. Per Med. 2015 Mar; 12(2):155-162. PMID: 29754537.
  40. Infante JR, Weiss GJ, Jones S, Tibes R, Bauer TM, Bendell JC, Hinson JM, Von Hoff DD, Burris HA, Orlemans EO, Ramanathan RK. Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours. Eur J Cancer. 2014 Nov; 50(17):2897-904. PMID: 25262379.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  41. Tran JQ, Dranikov A, Iannucci A, Wagner WP, LoBello J, Allen J, Weiss GJ. Heavy Metal Content in Thoracic Tissue Samples from Patients with and without NSCLC. Lung Cancer Int. 2014; 2014:853158. PMID: 26316947.
  42. Weiss GJ, Ganeshan B, Miles KA, Campbell DH, Cheung PY, Frank S, Korn RL. Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic. PLoS One. 2014; 9(7):e100244. PMID: 24987838.
    Citations: 21     Fields:    Translation:Humans
  43. Patnaik A, Weiss GJ, Papadopoulos KP, Hofmeister CC, Tibes R, Tolcher A, Isaacs R, Jac J, Han M, Payumo FC, Cotreau MM, Ramanathan RK. Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. Br J Cancer. 2014 Jul 15; 111(2):272-80. PMID: 24901237.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  44. Yamamoto S, Korn RL, Oklu R, Migdal C, Gotway MB, Weiss GJ, Iafrate AJ, Kim DW, Kuo MD. ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology. 2014 Aug; 272(2):568-76. PMID: 24885982.
    Citations: 23     Fields:    Translation:HumansCTClinical Trials
  45. Dearing KR, Sangal A, Weiss GJ. Maintaining clarity: Review of maintenance therapy in non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2):103-13. PMID: 24829857.
    Citations: 8     
  46. Northfelt DW, Ramanathan RK, Cohen PA, Von Hoff DD, Weiss GJ, Dietsch GN, Manjarrez KL, Randall TD, Hershberg RM. A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma. Clin Cancer Res. 2014 Jul 15; 20(14):3683-91. PMID: 24807889.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  47. Whitsett TG, Fortin Ensign SP, Dhruv HD, Inge LJ, Kurywchak P, Wolf KK, LoBello J, Kingsley CB, Allen JW, Weiss GJ, Tran NL. FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion. Clin Exp Metastasis. 2014 Aug; 31(6):613-23. PMID: 24710956.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  48. Curtis KK, Sarantopoulos J, Northfelt DW, Weiss GJ, Barnhart KM, Whisnant JK, Leuschner C, Alila H, Borad MJ, Ramanathan RK. Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. Cancer Chemother Pharmacol. 2014 May; 73(5):931-41. PMID: 24610297.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  49. Whitsett TG, Mathews IT, Cardone MH, Lena RJ, Pierceall WE, Bittner M, Sima C, LoBello J, Weiss GJ, Tran NL. Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response. Mol Cancer Res. 2014 Apr; 12(4):550-9. PMID: 24469836.
    Citations: 7     Fields:    Translation:HumansCells
  50. Dearing KR, Weiss GJ. Molecular characterization may be of PARAMOUNT importance. J Clin Oncol. 2014 Feb 10; 32(5):481-2. PMID: 24395858.
    Citations: 1     Fields:    Translation:Humans
  51. Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, Chen DM, Weiss GJ. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014 Jan; 70(1):60-9. PMID: 24189279.
    Citations: 26     Fields:    Translation:HumansCTClinical Trials
  52. Weiss GJ, Liang WS, Demeure MJ, Kiefer JA, Hostetter G, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Phillips L, Benson H, Reiman R, Baker A, Marsh V, Von Hoff DD, Carpten JD, Craig DW. A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges. PLoS One. 2013; 8(10):e76438. PMID: 24204627.
    Citations: 15     Fields:    Translation:HumansCells
  53. Kim TY, Jackson S, Xiong Y, Whitsett TG, Lobello JR, Weiss GJ, Tran NL, Bang YJ, Der CJ. CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth. Proc Natl Acad Sci U S A. 2013 Oct 15; 110(42):16868-73. PMID: 24082123.
    Citations: 15     Fields:    Translation:HumansCells
  54. Liang WS, Aldrich J, Tembe W, Kurdoglu A, Cherni I, Phillips L, Reiman R, Baker A, Weiss GJ, Carpten JD, Craig DW. Long insert whole genome sequencing for copy number variant and translocation detection. Nucleic Acids Res. 2014 Jan; 42(2):e8. PMID: 24071583.
    Citations: 8     Fields:    Translation:Humans
  55. Weiss GJ, Liman AK, Allen J, Cheung PY, Kukunoor RN. Squamous Cell Carcinoma of the Lung with Metastasis to the GI Tract Associated with EGFR Exon 19 Deletion. Case Rep Med. 2013; 2013:874836. PMID: 24171005.
    Citations: 4     
  56. Whitsett TG, Inge LJ, Dhruv HD, Cheung PY, Weiss GJ, Bremner RM, Winkles JA, Tran NL. Molecular determinants of lung cancer metastasis to the central nervous system. Transl Lung Cancer Res. 2013 Aug; 2(4):273-83. PMID: 25806243.
    Citations: 3     
  57. McKane A, Sima C, Fleck S, Weiss GJ. Examining the effect of teleconferences on oncology phase 1 trials. J Cancer. 2013; 4(6):464-7. PMID: 23901345.
  58. Mahadevan D, Chalasani P, Rensvold D, Kurtin S, Pretzinger C, Jolivet J, Ramanathan RK, Von Hoff DD, Weiss GJ. Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. Am J Clin Oncol. 2013 Jun; 36(3):239-43. PMID: 22441342.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  59. Christoforides A, Carpten JD, Weiss GJ, Demeure MJ, Von Hoff DD, Craig DW. Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs. BMC Genomics. 2013 May 04; 14:302. PMID: 23642077.
    Citations: 19     Fields:    Translation:Humans
  60. Jimeno A, Weiss GJ, Miller WH, Gettinger S, Eigl BJ, Chang AL, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis KD, Tibes R, Sharfman WH, Ross RW, Rudin CM. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res. 2013 May 15; 19(10):2766-74. PMID: 23575478.
    Citations: 46     Fields:    Translation:HumansCellsCTClinical Trials
  61. Caldwell S, Sima C, Jameson G, Fleck S, Weiss GJ. Factors influencing time to determination of the recommended phase 2 dose in phase 1 clinical trials. Am J Clin Oncol. 2013 Apr; 36(2):146-50. PMID: 22314002.
    Citations: 2     Fields:    Translation:Humans
  62. Weekes CD, Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, Lewis KD, Weiss GJ, Ramanathan RK, Dy GK, Ma WW, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh LT, Dubowy RL, Jeffers M, Rajagopalan P, Clendeninn NJ. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 01; 19(5):1232-43. PMID: 23434733.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  63. Kurywchak P, Kiefer J, Lenkiewicz E, Evers L, Holley T, Barrett M, Weiss GJ. Elucidating potentially significant genomic regions involved in the initiation and progression of undifferentiated pleomorphic sarcoma. Rare Tumors. 2013 Feb 11; 5(1):e14. PMID: 23772300.
  64. Weiss GJ, Chao J, Neidhart JD, Ramanathan RK, Bassett D, Neidhart JA, Choi CHJ, Chow W, Chung V, Forman SJ, Garmey E, Hwang J, Kalinoski DL, Koczywas M, Longmate J, Melton RJ, Morgan R, Oliver J, Peterkin JJ, Ryan JL, Schluep T, Synold TW, Twardowski P, Davis ME, Yen Y. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs. 2013 Aug; 31(4):986-1000. PMID: 23397498.
    Citations: 29     Fields:    Translation:HumansCTClinical Trials
  65. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, Paz-Ares L, Cho DC, Infante JR, Alsina M, Gounder MM, Falzone R, Harrop J, White AC, Toudjarska I, Bumcrot D, Meyers RE, Hinkle G, Svrzikapa N, Hutabarat RM, Clausen VA, Cehelsky J, Nochur SV, Gamba-Vitalo C, Vaishnaw AK, Sah DW, Gollob JA, Burris HA. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013 Apr; 3(4):406-17. PMID: 23358650.
    Citations: 132     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  66. Deeken JF, Slack R, Weiss GJ, Ramanathan RK, Pishvaian MJ, Hwang J, Lewandowski K, Subramaniam D, He AR, Cotarla I, Rahman A, Marshall JL. A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol. 2013 Mar; 71(3):627-33. PMID: 23274395.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  67. Weiss GJ. Doubling down with inhibitors of Notch and Hedgehog signaling pathways. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S409-10. PMID: 23160337.
    Citations:    Fields:    Translation:HumansCells
  68. Weiss GJ, Korn RL. Interpretation of PET scans: do not take SUVs at face value. J Thorac Oncol. 2012 Dec; 7(12):1744-1746. PMID: 23154544.
    Citations: 1     Fields:    Translation:Humans
  69. Mckane A, Sima C, Ramanathan RK, Jameson G, Mast C, White E, Fleck S, Downhour M, Von Hoff DD, Weiss GJ. Determinants of patient screen failures in Phase 1 clinical trials. Invest New Drugs. 2013 Jun; 31(3):774-9. PMID: 23135779.
    Citations: 1     Fields:    Translation:Humans
  70. Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M, Ramanathan RK, Borad MJ, Tibes R, Cohn A, Hinshaw I, Jotte R, Rosen LS, Hoch U, Eldon MA, Medve R, Schroeder K, White E, Von Hoff DD. A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin Cancer Res. 2013 Jan 01; 19(1):268-78. PMID: 23136196.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  71. Liang WS, Craig DW, Carpten J, Borad MJ, Demeure MJ, Weiss GJ, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer JA, Legendre C, Posner R, Hostetter GH, Baker A, Egan JB, Han H, Lake D, Stites EC, Ramanathan RK, Fonseca R, Stewart AK, Von Hoff D. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One. 2012; 7(10):e43192. PMID: 23071490.
    Citations: 25     Fields:    Translation:HumansCells
  72. Gordon MS, Rosen LS, Mendelson D, Ramanathan RK, Goldman J, Liu L, Xu Y, Gerson SL, Anthony SP, Figg WD, Spencer S, Adams BJ, Theuer CP, Leigh BR, Weiss GJ. A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Invest New Drugs. 2013 Jun; 31(3):714-23. PMID: 23054206.
    Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
  73. Arora S, Korn RL, Lenkiewicz E, Cherni I, Beach TG, Hostetter G, Barrett MT, Weiss GJ. Clonal evolution of a case of treatment refractory maxillary sinus carcinoma. PLoS One. 2012; 7(9):e45614. PMID: 23029135.
    Citations: 2     Fields:    Translation:Humans
  74. Thacker CA, Weiss GJ, Tibes R, Blaydorn L, Downhour M, White E, Baldwin J, Hoff DD, Korn RL. 18-FDG PET/CT assessment of basal cell carcinoma with vismodegib. Cancer Med. 2012 Oct; 1(2):230-6. PMID: 23342272.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  75. Weiss GJ, Liang WS, Izatt T, Arora S, Cherni I, Raju RN, Hostetter G, Kurdoglu A, Christoforides A, Sinari S, Baker AS, Metpally R, Tembe WD, Phillips L, Von Hoff DD, Craig DW, Carpten JD. Paired tumor and normal whole genome sequencing of metastatic olfactory neuroblastoma. PLoS One. 2012; 7(5):e37029. PMID: 22649506.
    Citations: 12     Fields:    Translation:HumansCells
  76. Whitsett TG, Cheng E, Inge L, Asrani K, Jameson NM, Hostetter G, Weiss GJ, Kingsley CB, Loftus JC, Bremner R, Tran NL, Winkles JA. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol. 2012 Jul; 181(1):111-20. PMID: 22634180.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  77. Weiss GJ, Korn RL. Metastatic basal cell carcinoma in the era of hedgehog signaling pathway inhibitors. Cancer. 2012 Nov 01; 118(21):5310-9. PMID: 22511370.
    Citations: 11     Fields:    Translation:HumansCells
  78. Weiss GJ, Donehower RC, Iyengar T, Ramanathan RK, Lewandowski K, Westin E, Hurt K, Hynes SM, Anthony SP, McKane S. Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer. Invest New Drugs. 2013 Feb; 31(1):136-44. PMID: 22492020.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  79. Looyenga BD, Hutchings D, Cherni I, Kingsley C, Weiss GJ, Mackeigan JP. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One. 2012; 7(2):e30820. PMID: 22319590.
    Citations: 44     Fields:    Translation:HumansCells
  80. Cheung PY, Szafranska-Schwarzbach AE, Schlageter AM, Andruss BF, Weiss GJ. No miR quirk: dysregulation of microRNAs in pancreatic ductal adenocarcinoma. Microrna. 2012; 1(1):49-58. PMID: 25048090.
    Citations:    Fields:    Translation:Humans
  81. Sheff KW, Hoda MA, Dome B, Hegedus B, Klepetko W, Weiss GJ. The role of microRNAs in the diagnosis and treatment of malignant pleural mesothelioma--a short review. Microrna. 2012; 1(1):40-8. PMID: 25048089.
    Citations:    Fields:    Translation:Humans
  82. Weiss GJ, Hidalgo M, Borad MJ, Laheru D, Tibes R, Ramanathan RK, Blaydorn L, Jameson G, Jimeno A, Isaacs JD, Scaburri A, Pacciarini MA, Fiorentini F, Ciomei M, Von Hoff DD. Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. Invest New Drugs. 2012 Dec; 30(6):2334-43. PMID: 22160853.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  83. Weiss GJ, Mita AC, Von Hoff DD. The hedgehog knows many tricks. Curr Drug Targets. 2011 Dec; 12(14):2091-5. PMID: 21777197.
    Citations:    Fields:    Translation:HumansAnimalsCells
  84. Bailey CH, Jameson G, Sima C, Fleck S, White E, Von Hoff DD, Weiss GJ. Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. J Cancer. 2012; 3:7-13. PMID: 22211140.
    Citations: 5     
  85. Raz G, Allen KE, Kingsley C, Cherni I, Arora S, Watanabe A, Lorenzo CD, Edwards V DK, Sridhar S, Hostetter G, Weiss GJ. Hedgehog signaling pathway molecules and ALDH1A1 expression in early-stage non-small cell lung cancer. Lung Cancer. 2012 May; 76(2):191-6. PMID: 22115706.
    Citations: 18     Fields:    Translation:HumansCells
  86. Weiss GJ. Targeting the Hedgehog and Notch signaling pathways. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1820-1. PMID: 22005544.
    Citations:    Fields:    Translation:HumansCells
  87. Bailey CH, Donovan PJ, Weiss GJ. Basal cell adenocarcinoma of the supraglottic larynx: treatment of recurrent disease with tamoxifen. Rare Tumors. 2011 Oct 21; 3(4):e55. PMID: 22355510.
  88. Weiss GJ, Lewandowski K, Oneall J, Kroll S. Resolution of Cullen's sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302. Dermatol Reports. 2011 Oct 05; 3(3):e56. PMID: 25386307.
    Citations: 1     
  89. Weiss GJ, Tibes R, Blaydorn L, Jameson G, Downhour M, White E, Caro I, Von Hoff DD. Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome. Dermatol Reports. 2011 Oct 05; 3(3):e55. PMID: 25386306.
    Citations: 1     
  90. Cherni I, Weiss GJ. miRNAs in lung cancer: large roles for small players. Future Oncol. 2011 Sep; 7(9):1045-55. PMID: 21919692.
    Citations: 10     Fields:    Translation:Humans
  91. Ramanathan RK, Stephenson JJ, Weiss GJ, Pestano LA, Lowe A, Hiscox A, Leos RA, Martin JC, Kirkpatrick L, Richards DA. A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy. Invest New Drugs. 2012 Aug; 30(4):1591-6. PMID: 21863237.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  92. Looyenga BD, Cherni I, Mackeigan JP, Weiss GJ. Tailoring tyrosine kinase inhibitors to fit the lung cancer genome. Transl Oncol. 2011 Apr 01; 4(2):59-70. PMID: 21461169.
    Citations: 7     
  93. Arora S, Ranade AR, Tran NL, Nasser S, Sridhar S, Korn RL, Ross JT, Dhruv H, Foss KM, Sibenaller Z, Ryken T, Gotway MB, Kim S, Weiss GJ. MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer. 2011 Dec 01; 129(11):2621-31. PMID: 21448905.
    Citations: 62     Fields:    Translation:HumansCells
  94. Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, Tibes R, Ramanathan RK, Lewandowski K, Jones SF, Lacouture ME, Langmuir VK, Lee H, Kroll S, Burris HA. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res. 2011 May 01; 17(9):2997-3004. PMID: 21415214.
    Citations: 40     Fields:    Translation:HumansCTClinical Trials
  95. Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol. 2011 Mar; 6(3):482-8. PMID: 21258252.
    Citations: 86     Fields:    Translation:Humans
  96. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011 Apr 15; 17(8):2502-11. PMID: 21300762.
    Citations: 154     Fields:    Translation:HumansCellsCTClinical Trials
  97. Shapiro GI, Tibes R, Gordon MS, Wong BY, Eder JP, Borad MJ, Mendelson DS, Vogelzang NJ, Bastos BR, Weiss GJ, Fernandez C, Sutherland W, Sato H, Pierceall WE, Weaver D, Slough S, Wasserman E, Kufe DW, Von Hoff D, Kawabe T, Sharma S. Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. Clin Cancer Res. 2011 May 15; 17(10):3431-42. PMID: 21220472.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  98. Ranade AR, Weiss GJ. Methods for microRNA microarray profiling. Methods Mol Biol. 2011; 700:145-52. PMID: 21204032.
    Citations: 1     Fields:    Translation:HumansCells
  99. Nasser S, Ranade AR, Sridhar S, Haney L, Korn RL, Gotway MB, Weiss GJ, Kim S. Biomarkers associated with metastasis of lung cancer to brain predict patient survival. Int J Data Min Bioinform. 2011; 5(3):287-307. PMID: 21805824.
    Citations: 2     Fields:    Translation:Humans
  100. Allen KE, Weiss GJ. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther. 2010 Dec; 9(12):3126-36. PMID: 20940321.
    Citations: 43     Fields:    Translation:HumansAnimalsCells
  101. Weiss GJ, Alarcon A, Halepota M, Penny RJ, Von Hoff DD. Molecular characterization of interdigitating dendritic cell sarcoma. Rare Tumors. 2010 Sep 30; 2(3):e50. PMID: 21139965.
    Citations: 6     
  102. Weiss GJ. Thymic carcinoma: current and future therapeutic interventions. Expert Opin Investig Drugs. 2010 Aug; 19(8):1007-16. PMID: 20629617.
    Citations: 2     Fields:    Translation:Humans
  103. Ranade AR, Cherba D, Sridhar S, Richardson P, Webb C, Paripati A, Bowles B, Weiss GJ. MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J Thorac Oncol. 2010 Aug; 5(8):1273-8. PMID: 20548249.
    Citations: 27     Fields:    Translation:Humans
  104. Weiss GJ, Von Hoff DD. Hunting the hedgehog pathway. Clin Pharmacol Ther. 2010 Jun; 87(6):743-7. PMID: 20410878.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  105. Goldberg LH, Firoz BF, Weiss GJ, Blaydorn L, Jameson G, Von Hoff DD. Basal cell nevus syndrome: a brave new world. Arch Dermatol. 2010 Jan; 146(1):17-9. PMID: 20083687.
    Citations: 1     Fields:    Translation:Humans
  106. Paripati A, Kingsley C, Weiss GJ. Pathway targets to explore in the treatment of small cell and large cell lung cancers. J Thorac Oncol. 2009 Nov; 4(11):1313-21. PMID: 19812504.
    Citations: 1     Fields:    Translation:HumansCells
  107. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC, de Sauvage FJ, Low JA. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17; 361(12):1164-72. PMID: 19726763.
    Citations: 331     Fields:    Translation:HumansCellsCTClinical Trials
  108. Nelson KM, Weiss GJ. MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther. 2008 Dec; 7(12):3655-60. PMID: 19074842.
    Citations: 82     Fields:    Translation:HumansAnimalsCells
  109. Weiss GJ, Kingsley C. Pathway targets to explore in the treatment of non-small cell lung cancer. J Thorac Oncol. 2008 Nov; 3(11):1342-52. PMID: 18978571.
    Citations: 1     Fields:    Translation:HumansCells
  110. Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA, Haney J, Helfrich BA, Kato H, Hirsch FR, Franklin WA. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol. 2008 Jun; 19(6):1053-9. PMID: 18304967.
    Citations: 78     Fields:    Translation:HumansCells
  111. Weiss GJ. Continuous-flow ventricular assist device. N Engl J Med. 2007 Nov 29; 357(22):2305; author reply 2305-6. PMID: 18046035.
    Citations:    Fields:    Translation:Humans
  112. Weiss GJ, Vokes EE, Bunn PA, Magree L, Rusk J, Albert D, Kelly K. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. J Thorac Oncol. 2007 Oct; 2(10):933-8. PMID: 17909356.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  113. Weiss GJ, Zeng C, Kelly K, Tran ZV, Bunn PA. Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer. Clin Lung Cancer. 2007 Mar; 8(5):335-8. PMID: 17562234.
    Citations: 4     Fields:    Translation:Humans
  114. Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F, Nguyen B, Paul S, McAndrews P, Hanna N, Kelly K, Bunn PA. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007 Mar; 18(3):453-60. PMID: 17322539.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  115. Escobar GA, Robinson WA, Nydam TL, Heiple DC, Weiss GJ, Buckley L, Gonzalez R, McCarter MD. Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report. BMC Cancer. 2007 Jan 17; 7:13. PMID: 17229322.
    Citations: 9     Fields:    Translation:Humans
  116. Weiss GJ, Bunn PA, Camidge DR. From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer. Oncology (Williston Park). 2006 Nov; 20(12):1515-24; discussion 1524-5, 1530, 1535. PMID: 17153906.
    Citations: 3     Fields:    Translation:Humans
  117. Weiss GJ, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn LH, Nguyen B, Paul S, McAndrews P, Bunn PA, Kelly K. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006 Sep 20; 24(27):4405-11. PMID: 16983108.
    Citations: 34     Fields:    Translation:Humans
  118. Weiss G, Shemer A, Trau H. Yellowish, verrucous lesions on the scalp. Am Fam Physician. 2005 Mar 01; 71(5):961-2. PMID: 15768626.
    Citations:    Fields:    Translation:Humans
  119. Weiss G. Non-Psychogenic Polydipsia With Hyponatremia. Internet J Nephrol. 2004; 2(1):1-10. View Publication.
  120. Weiss G, Confino Y, Shemer A, Trau H. Cutaneous manifestations in the cardiofaciocutaneous syndrome, a variant of the classical Noonan syndrome. Report of a case and review of the literature. J Eur Acad Dermatol Venereol. 2004 May; 18(3):324-7. PMID: 15096145.
    Citations: 5     Fields:    Translation:Humans
  121. Shemer A, Weiss G, Trau H. Oral terbinafine in the treatment of onychomycosis: a comparison of continuous and extended-pause regimens. J Eur Acad Dermatol Venereol. 2002 May; 16(3):299-301. PMID: 12195585.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  122. Weiss G, Shemer A, Trau H. The Koebner phenomenon: review of the literature. J Eur Acad Dermatol Venereol. 2002 May; 16(3):241-8. PMID: 12195563.
    Citations: 38     Fields:    Translation:Humans
  123. Shemer A, Weiss G, Amichai B, Kaplan B, Trau H. Azelaic acid (20%) cream in the treatment of acne vulgaris. J Eur Acad Dermatol Venereol. 2002 Mar; 16(2):178-9. PMID: 12046832.
    Citations: 2     Fields:    Translation:Humans
  124. Shemer A, Weiss G, Confino Y, Trau H. The hyper-IgE syndrome. Two cases and review of the literature. Int J Dermatol. 2001 Oct; 40(10):622-8. PMID: 11737420.
    Citations: 3     Fields:    Translation:Humans
  125. Shemer A, Weiss G, Trau H. Wolf's isotopic response: a case of zosteriform lichen planus on the site of healed herpes zoster. J Eur Acad Dermatol Venereol. 2001 Sep; 15(5):445-7. PMID: 11763387.
    Citations: 3     Fields:    Translation:Humans
  126. Weiss G, Shemer A, Confino Y, Kaplan B, Trau H. Wells' syndrome: report of a case and review of the literature. Int J Dermatol. 2001 Feb; 40(2):148-52. PMID: 11328401.
    Citations: 4     Fields:    Translation:Humans
  127. Cohen B, Weiss G, Yin H. Basal cell carcinoma (BCC) causing spinal cord compression. Dermatol Online J. 2000 Sep; 6(1):12. PMID: 11328622.
    Citations: 2     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Weiss's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (410)
Co-Authors (11)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.